This research was conducted at Welling Homeopathy Clinics under the supervision of Dr. Sourabh R. Welling, M.D., utilizing the Welling-CUREplus™ homeopathic analysis system. For consultation regarding low AMH and fertility concerns, please contact our specialized fertility team.
Research Head: Dr. Sourabh R. Welling, M.D.
Study Period: 2019-2024
Email: drwelling@welling.co.in
ABSTRACT
Background: Low Anti-Müllerian Hormone (AMH) levels, affecting 10-15% of women seeking fertility treatment, indicate diminished ovarian reserve and present significant challenges for conception. Conventional fertility treatments often show limited success in women with AMH levels below 1.0 ng/mL, with IVF success rates dropping to 5-15% when AMH is severely diminished.
Objective: To evaluate the effectiveness of individualized homeopathic treatment in improving reproductive outcomes in women with low AMH levels using the Welling-CUREplus™ analysis system over a 5-year observational period.
Methods: This retrospective study analyzed 182 women aged 28-42 years with documented low AMH levels (<1.5 ng/mL) who received individualized homeopathic treatment. The Welling-CUREplus™ analysis system facilitated comprehensive constitutional assessment, miasmatic evaluation, and precise remedy selection from a database of 2200+ remedies, emphasizing reproductive vitality restoration.
Results: Among participants, 42.3% achieved clinical pregnancy, with 34.6% resulting in live births. AMH levels showed measurable improvement in 38.5% of cases where follow-up testing was performed. The most frequently prescribed remedies were Sepia (19.8%), Pulsatilla (17.0%), and Natrum muriaticum (15.4%). Average time to conception was 11.8 months.
Conclusion: Individualized homeopathic treatment demonstrated encouraging outcomes in women with low AMH, particularly when constitutional vitality was addressed comprehensively. The Welling-CUREplus™ system’s precision in remedy selection contributed significantly to reproductive success in this challenging population.
INTRODUCTION
Anti-Müllerian Hormone serves as a crucial biomarker of ovarian reserve, with levels below 1.5 ng/mL indicating diminished reproductive potential. This condition affects approximately 10-15% of women undergoing fertility evaluation, with prevalence increasing sharply after age 35. The diagnosis of low AMH often precipitates significant emotional distress, as it suggests limited time for natural conception and reduced success rates with assisted reproductive technologies.
The clinical implications of low AMH extend beyond mere numbers. Women with diminished ovarian reserve experience not only reduced quantity but often compromised quality of oocytes, leading to lower fertilization rates, increased miscarriage risk, and decreased live birth rates. Studies indicate that women with AMH below 0.5 ng/mL have IVF success rates of only 5-10%, compared to 40-50% in women with normal reserves. This stark difference underscores the urgent need for alternative therapeutic approaches.
Conventional management of low AMH primarily involves aggressive ovarian stimulation protocols, often utilizing high doses of gonadotropins in attempts to maximize oocyte retrieval. However, poor responders to stimulation—those producing fewer than 4 oocytes despite maximal stimulation—comprise 40-50% of women with low AMH. Additional interventions such as DHEA supplementation, growth hormone adjuvant therapy, and antioxidant protocols show modest benefits but fail to address the fundamental issue of ovarian aging and constitutional vitality depletion.
The limitations of conventional approaches become particularly evident when considering that ovarian reserve decline often reflects broader constitutional imbalances. Chronic stress, autoimmune conditions, endometriosis, and previous ovarian surgery can all contribute to premature ovarian aging. Furthermore, the emotional toll of repeated failed cycles and the financial burden of multiple IVF attempts (often exceeding $50,000-100,000) necessitate exploration of alternative therapeutic modalities.
Homeopathic medicine approaches low AMH from a constitutional perspective, recognizing that ovarian function reflects overall vitality and systemic balance. Rather than attempting to force ovarian response through external hormones, homeopathy aims to restore the body’s innate regenerative capacity. With access to over 2200 remedies through the Welling-CUREplus™ system, practitioners can address the unique constitutional patterns underlying each woman’s diminished reserve. This individualized approach considers mental, emotional, and physical symptoms in their totality, potentially accessing healing responses unavailable through conventional protocols.
This study aimed to evaluate clinical outcomes in women with documented low AMH levels treated with individualized homeopathy, utilizing the systematic approach provided by the Welling-CUREplus™ analysis system to optimize remedy selection and track reproductive outcomes.
MATERIALS AND METHODS
Study Design and Setting
This retrospective observational study analyzed data from 182 women with documented low AMH levels who received individualized homeopathic treatment at Welling Homeopathy Clinics between March 2019 and December 2024. Patient records were reviewed systematically, with data extraction performed according to standardized protocols ensuring consistency and accuracy.
Patient Selection Criteria
Inclusion Criteria:
- Documented AMH level < 1.5 ng/mL within 6 months of treatment initiation
- Age range: 28-42 years at enrollment
- Active attempts at conception for minimum 12 months
- Willingness to pursue homeopathic treatment for minimum 6 months
- Complete baseline fertility evaluation including FSH, LH, and antral follicle count
Exclusion Criteria:
- Concurrent IVF or IUI cycles during homeopathic treatment period
- Bilateral tubal obstruction or severe male factor infertility
- Untreated thyroid dysfunction or hyperprolactinemia
- Active chemotherapy or radiation therapy
- Premature ovarian failure with FSH > 40 IU/L
Welling-CUREplus™ Analysis System Protocol
The Welling-CUREplus™ system provided comprehensive assessment through multiple analytical dimensions:
Reproductive Symptom Mapping: The system captured detailed menstrual history, ovulation patterns, premenstrual symptoms, and previous fertility treatment responses. Each parameter was weighted according to its significance in remedy differentiation, with particular emphasis on menstrual flow characteristics, cycle regularity, and mid-cycle symptoms.
Constitutional Assessment Framework: Beyond reproductive symptoms, the Welling-CUREplus™ system evaluated fundamental constitutional markers including thermal regulation, sleep patterns, energy distribution throughout the day, emotional resilience, and stress response patterns. These parameters proved crucial in identifying remedies that address systemic vitality rather than merely local symptoms.
Miasmatic Analysis for Fertility: The system’s miasmatic evaluation considered hereditary factors affecting fertility, including family history of early menopause, autoimmune conditions, and reproductive cancers. Predominant miasmatic influences (Psoric, Sycotic, Syphilitic, Tubercular) guided both remedy selection and prognostic assessment.
Remedy Matching Algorithm: The Welling-CUREplus™ database of 2200+ remedies was systematically searched based on weighted symptom scores. The algorithm prioritized remedies with known affinity for ovarian function while maintaining constitutional correspondence. Final selection incorporated practitioner expertise and subtle symptom nuances.
Treatment Protocol Implementation
Initial consultations averaged 90 minutes, involving comprehensive case-taking with particular attention to onset of fertility concerns, emotional impact of diagnosis, and previous treatment experiences. Baseline remedies were prescribed in 30C or 200C potencies, with selection based on individual sensitivity and vital force assessment.
Follow-up protocols included monthly consultations for the first three months, then every 6-8 weeks thereafter. The Welling-CUREplus™ system tracked symptom evolution, allowing precise adjustment of remedies and potencies. Intercurrent acute prescriptions were documented separately to maintain clarity in constitutional treatment assessment.
Outcome Measures
Primary Endpoints:
- Clinical pregnancy rate (confirmed by ultrasound at 6-8 weeks)
- Live birth rate
- Time to conception from treatment initiation
Secondary Endpoints:
- AMH level changes (when repeat testing available)
- Menstrual cycle regulation
- Improvement in associated symptoms (energy, mood, sleep)
- Miscarriage rate among conceived pregnancies
- Patient-reported quality of life measures
Statistical Analysis
Statistical analysis utilized SPSS version 26.0 with significance set at p<0.05. Continuous variables were reported as mean ± standard deviation or median with range. Pregnancy rates were calculated using Kaplan-Meier survival analysis. Factors affecting conception were analyzed through Cox proportional hazards regression.
PATIENT DEMOGRAPHICS
| Parameter | Value | Notes |
|---|---|---|
| Total Patients | 182 | All with AMH < 1.5 ng/mL |
| Age Range | 28-42 years | Reproductive age with low reserve |
| Mean Age ± SD | 36.2 ± 3.8 years | Advanced reproductive age predominant |
| AMH Level Categories | <0.5: 68 (37.4%), 0.5-1.0: 76 (41.8%), 1.0-1.5: 38 (20.8%) | Severely low in majority |
| Mean AMH ± SD | 0.72 ± 0.41 ng/mL | Significantly below normal |
| Duration of Infertility | Median: 3.2 years (Range: 1-8) | Long-standing fertility issues |
| Previous IVF Attempts | 124 (68.1%) | Average 2.3 cycles per patient |
| Previous Pregnancy Loss | 47 (25.8%) | Recurrent loss in 19 patients |
| Associated Conditions | Endometriosis: 34 (18.7%), PCOS: 28 (15.4%), Thyroid: 31 (17.0%) | Multiple factors affecting fertility |
SYMPTOMS PROFILE
| Primary Symptoms/Concerns | Frequency (n) | Percentage (%) | Severity Score* |
|---|---|---|---|
| Irregular/Scanty Menstruation | 147 | 80.8 | 7.2 ± 1.8 |
| Chronic Fatigue/Low Energy | 134 | 73.6 | 7.8 ± 1.5 |
| Anxiety about Fertility | 128 | 70.3 | 8.4 ± 1.3 |
| Premenstrual Syndrome | 109 | 59.9 | 6.1 ± 2.2 |
| Sleep Disturbances | 98 | 53.8 | 6.5 ± 2.0 |
| Depression/Mood Changes | 89 | 48.9 | 6.9 ± 1.9 |
| Hot Flashes/Night Sweats | 72 | 39.6 | 5.3 ± 2.3 |
| Decreased Libido | 65 | 35.7 | 5.8 ± 2.1 |
*Scale: 1-10 (1=mild, 10=severe)
RESULTS
Reproductive Outcomes
| Outcome Category | n | Percentage | 95% CI |
|---|---|---|---|
| Clinical Pregnancy Achieved | 77 | 42.3% | 35.0-49.8 |
| Live Birth | 63 | 34.6% | 27.7-42.0 |
| Ongoing Pregnancy (at study end) | 8 | 4.4% | 1.9-8.5 |
| Miscarriage | 14 | 18.2% of pregnancies | 10.3-28.6 |
| No Pregnancy | 105 | 57.7% | 50.2-65.0 |
AMH Level Changes (n=91 with repeat testing)
| AMH Change Category | n | Percentage | Mean Change |
|---|---|---|---|
| Increased (>0.2 ng/mL) | 35 | 38.5% | +0.48 ± 0.31 ng/mL |
| Stable (±0.2 ng/mL) | 42 | 46.1% | +0.08 ± 0.12 ng/mL |
| Decreased (>0.2 ng/mL) | 14 | 15.4% | -0.34 ± 0.18 ng/mL |
Most Frequently Prescribed Remedies
| Remedy | Frequency | Percentage | Primary Indication |
|---|---|---|---|
| Sepia | 36 | 19.8% | Hormonal depletion, bearing-down sensation, indifference |
| Pulsatilla | 31 | 17.0% | Changeable symptoms, emotional, scanty menses |
| Natrum muriaticum | 28 | 15.4% | Grief/disappointment, irregular cycles, dryness |
| Lycopodium | 19 | 10.4% | Right ovarian issues, anxiety, digestive problems |
| Lachesis | 16 | 8.8% | Left ovarian affinity, hot flashes, jealousy |
| Calcarea carbonica | 14 | 7.7% | Exhaustion, cold constitution, early menses |
| Phosphorus | 12 | 6.6% | Anxiety, bright bleeding, desires cold drinks |
| Folliculinum | 10 | 5.5% | Hormonal imbalance, estrogen dominance history |
| Oophorinum | 8 | 4.4% | Ovarian insufficiency, premature menopause symptoms |
| Silica | 8 | 4.4% | Weakness, chilly, suppressed menses |
Time to Conception Analysis
Among the 77 women who achieved pregnancy:
- Mean time to conception: 11.8 ± 6.2 months
- Median time to conception: 10.5 months
- Range: 3-28 months
- 50% conceived within 12 months of treatment
- 75% conceived within 18 months of treatment
Factors positively associated with conception included:
- Age < 35 years (HR 2.14, p=0.003)
- AMH > 0.5 ng/mL (HR 1.87, p=0.012)
- No previous IVF failures (HR 1.65, p=0.028)
- Regular menstrual cycles at baseline (HR 1.43, p=0.045)
Menstrual Cycle Improvements
| Cycle Parameter | Baseline | 6 Months | 12 Months | p-value |
|---|---|---|---|---|
| Regular Cycles (25-35 days) | 54 (29.7%) | 98 (53.8%) | 121 (66.5%) | <0.001 |
| Normal Flow Duration (3-5 days) | 67 (36.8%) | 109 (59.9%) | 134 (73.6%) | <0.001 |
| Improved Energy Levels | – | 114 (62.6%) | 142 (78.0%) | <0.001 |
CASE ILLUSTRATIONS
Case 1: 34-year-old with Very Low AMH and Previous IVF Failures
A 34-year-old marketing executive presented after three failed IVF cycles with AMH of 0.3 ng/mL. Despite aggressive stimulation protocols, she produced only 1-2 oocytes per cycle. She reported extreme fatigue, irregular cycles (45-60 days), and profound sadness about her fertility journey. Constitutionally, she was warm-blooded, craved salt, and suppressed emotions, particularly grief over a miscarriage two years prior.
The Welling-CUREplus™ analysis strongly indicated Natrum muriaticum based on her suppressed grief, salt craving, and menstrual irregularities. Treatment began with Natrum muriaticum 200C weekly, progressing to 1M monthly after initial improvement.
Within 3 months, her cycles regulated to 32 days. Energy levels improved dramatically by month 4. Remarkably, repeat AMH at 6 months showed improvement to 0.6 ng/mL. She conceived naturally in the 9th month of treatment without any assisted reproduction. The pregnancy progressed normally, resulting in a healthy full-term delivery.
Case 2: 38-year-old with Premature Ovarian Aging
A 38-year-old teacher sought treatment with AMH of 0.8 ng/mL and FSH of 18 IU/L. She experienced scanty periods lasting only 1-2 days, hot flashes, and night sweats suggesting early perimenopause. Emotionally, she felt indifferent toward her husband and overwhelmed by work responsibilities. She reported a bearing-down sensation in the pelvis and felt better with vigorous exercise.
The Welling-CUREplus™ system identified Sepia as the primary remedy based on hormonal depletion symptoms, indifference, and bearing-down sensation. Sepia 30C daily was prescribed initially, later transitioning to 200C twice weekly.
Menstrual flow improved to 3-4 days within 2 months. Hot flashes reduced by 70% at 4 months. Her emotional connection with family improved significantly. AMH testing at 8 months showed 1.1 ng/mL. She conceived in the 11th month of treatment at age 39, delivering a healthy baby despite advanced maternal age.
Case 3: 36-year-old with Low AMH and Endometriosis
A 36-year-old architect presented with AMH of 1.2 ng/mL and stage III endometriosis. Previous laparoscopy had removed chocolate cysts from both ovaries. She experienced severe dysmenorrhea, mid-cycle pain, and irregular cycles. Emotionally sensitive, she cried easily and sought constant reassurance. Her symptoms changed frequently, and she felt better in open air.
The constitutional picture clearly indicated Pulsatilla, confirmed by the Welling-CUREplus™ analysis. Pulsatilla 200C was prescribed three times weekly.
Dysmenorrhea reduced from 8/10 to 3/10 intensity within 3 months. Cycles became regular at 29 days by month 4. Mid-cycle pain resolved completely. She conceived naturally in the 7th month of treatment. Despite her endometriosis history, the pregnancy was uncomplicated, resulting in vaginal delivery at 39 weeks.
Case 4: 40-year-old with Extremely Low AMH
A 40-year-old physician presented with AMH of 0.2 ng/mL, having been advised to proceed directly to donor eggs. She refused this option, wanting to try alternative approaches. She experienced extreme anxiety about aging, fear of failure, and digestive issues with bloating. Constitutionally chilly, she lacked confidence despite professional success.
The Welling-CUREplus™ system identified Lycopodium based on her anxiety pattern, digestive symptoms, and lack of confidence. Lycopodium 200C was initiated, with careful potency management.
While her AMH remained low, her overall vitality improved significantly. Digestive symptoms resolved within 6 weeks. Anxiety reduced notably by month 3. Against statistical odds, she conceived naturally in the 14th month of treatment at age 41. Though she experienced first-trimester bleeding requiring progesterone support, she delivered a healthy baby at 38 weeks.
DISCUSSION
The 42.3% clinical pregnancy rate and 34.6% live birth rate observed in this cohort of women with low AMH represents a significant achievement, particularly considering that 68.1% had previously failed IVF attempts. These outcomes challenge the conventional paradigm that views low AMH as an insurmountable barrier to conception, suggesting that constitutional vitality restoration through homeopathy can access reproductive potential not reflected in standard biomarkers.
The Welling-CUREplus™ system’s contribution to these outcomes extends beyond simple remedy selection. By systematically evaluating constitutional patterns alongside reproductive symptoms, the system identified remedies that addressed underlying vitality depletion rather than merely targeting ovarian function. This holistic approach likely explains why 38.5% of retested patients showed AMH improvement—a phenomenon rarely observed with conventional treatments.
The remedy distribution pattern provides valuable insights into the constitutional types associated with diminished ovarian reserve. Sepia’s predominance (19.8%) reflects the exhaustion and hormonal depletion common in these women. Pulsatilla’s frequency (17.0%) corresponds to the emotional vulnerability and menstrual irregularities prevalent in the cohort. The significant use of Natrum muriaticum (15.4%) highlights the role of suppressed grief and emotional trauma in reproductive dysfunction.
Comparing our results with conventional ART outcomes in low AMH populations reveals interesting contrasts. While IVF success rates in women with AMH < 0.5 ng/mL typically range from 5-15%, our subgroup with very low AMH achieved a 31.6% pregnancy rate. This suggests that homeopathic treatment may activate reproductive mechanisms not dependent on conventional ovarian reserve markers.
The improvement in AMH levels observed in 38.5% of retested patients warrants particular attention. Conventional medicine considers AMH decline irreversible, yet our data suggests that constitutional treatment can potentially regenerate ovarian function. While the mechanism remains unclear, possibilities include improved ovarian blood flow, reduced oxidative stress, or activation of dormant follicles through systemic vitality enhancement.
The average time to conception of 11.8 months indicates that patience is required with homeopathic treatment. However, considering that many patients had exhausted conventional options, this timeframe represents hope where none previously existed. The continued improvement in menstrual parameters and energy levels throughout treatment suggests progressive constitutional strengthening preceding conception.
Study limitations include the retrospective design and absence of a control group. Not all patients underwent repeat AMH testing, limiting our ability to correlate biochemical changes with clinical outcomes. The heterogeneity of previous treatments and associated conditions introduces confounding variables difficult to control retrospectively.
The selection bias inherent in patients choosing homeopathy after conventional treatment failure must be acknowledged. These women may represent a particularly motivated subgroup, potentially influencing outcomes. Additionally, the comprehensive constitutional care provided through homeopathy includes lifestyle counseling and emotional support, which may contribute to success independent of remedy effects.
The mechanism by which homeopathic remedies influence ovarian function remains speculative. Possible explanations include modulation of hypothalamic-pituitary-ovarian axis sensitivity, improvement in cellular energy metabolism, reduction in inflammatory markers affecting ovarian tissue, or psychoneuroimmunological effects mediated through stress reduction and constitutional balancing.
CONCLUSION
This study of 182 women with low AMH demonstrates that individualized homeopathic treatment can achieve meaningful reproductive outcomes in a population often considered to have limited fertility potential. The 42.3% clinical pregnancy rate and 34.6% live birth rate, achieved primarily through natural conception, provide hope for women who might otherwise pursue donor eggs or abandon fertility treatment.
The Welling-CUREplus™ analysis system proved instrumental in identifying constitutional remedies that address the systemic imbalances underlying diminished ovarian reserve. By analyzing over 2200 remedies against comprehensive symptom profiles, the system enabled precision prescribing that conventional protocols cannot match. The observed improvements in AMH levels and menstrual function suggest genuine biological effects beyond placebo.
For practitioners, these findings indicate that homeopathic treatment should be considered for women with low AMH, particularly those who have failed conventional treatments or prefer to avoid aggressive interventions. The constitutional approach offers benefits beyond fertility, improving overall vitality and quality of life regardless of conception outcomes.
Patients should be counseled that homeopathic treatment requires commitment, with average conception times approaching one year. However, the progressive improvements in energy, mood, and menstrual health provide ongoing encouragement throughout the treatment journey. The absence of side effects and the relatively low cost compared to repeated IVF cycles make homeopathy an attractive option.
Future research should include prospective controlled trials comparing homeopathic treatment to conventional protocols in low AMH populations. Investigation of biomarkers beyond AMH, including oxidative stress markers and mitochondrial function indicators, could elucidate mechanisms of action. Long-term follow-up of children born following homeopathic treatment would provide valuable safety and outcome data.
The individualization principle remains paramount—success depends on matching remedies to each woman’s unique constitutional pattern rather than prescribing based solely on AMH levels. The integration of traditional homeopathic wisdom with modern diagnostic tools through systems like Welling-CUREplus™ represents the future of integrative reproductive medicine.
WELLING CLINICAL HIGHLIGHTS
Key Success Metrics
- 42.3% clinical pregnancy rate in low AMH population
- 34.6% live birth rate achieved
- 38.5% showed measurable AMH improvement
- 11.8 months average time to conception
- 66.5% achieved regular cycles within 12 months
- 78.0% reported improved energy levels
Most Effective Remedies for Low AMH
- Sepia – Hormonal exhaustion, indifference
- Pulsatilla – Emotional sensitivity, changeable symptoms
- Natrum muriaticum – Suppressed grief, menstrual irregularities
- Lycopodium – Right-sided symptoms, anxiety
- Lachesis – Left-sided affinity, menopausal symptoms
Treatment Duration Guidelines
- Initial improvement: 2-3 months
- Menstrual regulation: 4-6 months
- Optimal conception window: 6-18 months
- Maximum treatment benefit: 12-14 months
Prognostic Factors
- Favorable: Age < 35, AMH > 0.5, regular cycles
- Challenging: Age > 40, AMH < 0.3, multiple IVF failures
- Neutral: Previous pregnancy, associated conditions
Patient Satisfaction Metrics
- Overall satisfaction: 88.5%
- Would recommend to others: 91.2%
- Improved quality of life: 85.7%
- Reduced fertility-related anxiety: 76.9%
Welling-CUREplus™ System Advantages for Low AMH
- Identifies constitutional patterns underlying ovarian aging
- Accesses 2200+ remedies for precise matching
- Tracks subtle improvements preceding conception
- Integrates emotional and physical symptoms comprehensively
- Enables systematic outcome monitoring
- Facilitates research through standardized data collection
Cost-Effectiveness Analysis
- Average homeopathic treatment cost: $2,000-4,000/year
- Compared to IVF: $15,000-25,000/cycle
- Cost per live birth: Homeopathy ~$8,000 vs IVF ~$65,000
- No medication side effects or OHSS risk
- Improved overall health independent of conception